1.1 Shares allotted as fully paid up by way of Bonus Shares for the
 Period of five years immediately preceding 31st March,2012;
 
 The Company allotted 5,76,33,250 Equity Shares as fully paid-up Bonus
 Shares by utilization of Securities Premium in April 2007 except this
 no shares have been allotted by way of bonus during the preceding
 period of the five years.
 
 1.2 Rights, preferences and restrictions attached to the Ordinary
 Shares
 
 The Shares of the Company, having par value of Rs.1.00 per share, rank
 pari passu in all respects including voting rights and entitlement to
 dividend.
 
 Terms and Conditions of Options Granted
 
 Each Option entitles the holder thereof to apply for and be allotted
 one Equity Shares of the Company of Rs.1.00 each upon payment of the
 exercise price during the exercise period. The exercise period
 commences from the date of vesting of the Options and expires at the
 end of three years from the date of vesting in respect of Options
 granted under the Suven Employee Stock Option Scheme -2004
 
 The vesting period for conversion of Options is as follows:
 
 On completion of 24 months from the date of grant of the Options: 25%
 vests On completion of 36 months from the date of grant of the Options:
 35% vests On completion of 48 months from the date of grant of the
 Options: 40% vests
 
 The Options have been granted at the ''market price'' as defined from
 time to time under the Securities and Exchange Board of India (Employee
 Stock Option Scheme and Employee Stock Purchase Scheme) Guidelines,
 1999.
 
 Capital Work in progress for the year 2011-12 Rs.2735.65 lakhs (Previous
 year Rs.335.62 lakhs)
 
 Depreciation on R & D Equipment of Rs.254.74 lakhs has been added to R &
 D Expenses (Previous Year Rs.246.02 lakhs) Amalgamated Assets pertains to
 M/s. Suven Nishtaa Pharma Pvt. Ltd.
 
 * depredation for the year includes depreciation on account of
 amalgamation for a period of 3 months.
 
 In accordance with Accounting Standard 15 Employees Benefits, the
 Company has classified various benefits provided to employees as under:
 
 b) Other Employee Benefit Plan
 
 The liability for Leave Encashment as at the year end is Rs.186.70 Lakhs
 (previous year Rs.142.06 Lakhs) and the assumptions are as same as above.
 
 2.1 Contingent Liabilities
 
                                                           (Rs. in lakhs)
 
 Particulars                             Year Ended         Year Ended
                                            2011-12            2010-11
 
 Corporate Guarantee 
 given on behalf 
 of Suven Nishtaa Pharma 
 Private Limited                              Nil              2375.00
 
 Un expired Letters of Credit                 358.71            478.31
 
 Disputed Service Tax demands 
 against which company is in appeal           Nil                38.25
 
 Disputed VAT demands against 
 which company is in appeal                   Nil                 7.53
 
 2.2 Capital commitments not provided for on account of pending
 execution [net of advance Rs.225.19 Lakhs (Previous year Rs.2.80 Lakhs)]
 
 2.3 During the year Unclaimed Dividend pertaining to 2003-04 amounting
 to Rs.0.91 Lakhs has been transferred to Investor Education and
 Protection Fund. There are no amounts due and outstanding to be
 credited to the Investor Education and Protection Fund as of 31st March
 2012 (Previous year Nil).
 
 2.4 There are no delays in payments to Micro and Small enterprises as
 required to be disclosed under the Micro, Small and Medium Enterprises
 Development Act, 2006. The information regarding Micro and Small
 enterprises has been determined to the extent such parties have been
 identified on the basis of information available with the Company.
 This has been relied upon by the Auditors.
 
 The Company has paid a minimum remuneration of Rs.4.00 Lakhs per month to
 Mr. Venkateswarlu Jasti, Chairman & CEO of the Company and Rs.3.05 Lakhs
 per month to Mrs. Sudha Rani Jasti, Whole-time Director of the Company
 for the financial year ending 31st March 2012.
 
 The above remuneration excludes provision for gratuity, since the
 liability is determined for all the employees on an independent
 actuarial valuation basis. The specific amount of gratuity Directors
 cannot be ascertained separately.
 
 2.5 National Savings Certificates to the extent of Rs.3,000/- have been
 pledged with Government Authorities.
 
 2.6 Employee Stock Option Scheme
 
 The Company instituted the Employees Stock Option 2004 plan for all
 eligible employees. The Scheme covers all eligible employees of Suven
 Life Sciences Limited and its subsidiary.
 
 2.7 Excise Duty amounting to Rs.18.38 Lakhs on Closing Stock of finished
 Goods has been provided during the year to comply with '' Guidance Note
 on Accounting treatment for Excise duty'' issued by Institute of
 Chartered Accountants of India.
 
 2.8 Hedging and Derivatives
 
 Company has entered into Forward Exchange contract, being derivative
 instruments for hedging purpose and not intended for trading or
 speculation purposes, to establish the amount of currency in Indian
 Rupees required or available at the settlement date of certain payables
 and receivables. The following are the outstanding Forward Exchange
 Contracts as on 31st March 2012, entered into by the company;
 
 A) Primary Segment:
 
 Business Segment
 
 Segments have been identified and reported taking into account the
 nature of products, the differing risk and returns, the organization
 structure, and the internal financial reporting scheme. The company has
 identified the following segments as its reportable segments:
 
 a) Manufacturing (CRAMS)
 
 b) Services (DDDSS)
 
 c) Research and Development
 
 I.  Manufacturing (CRAMS) - Bulk Drugs & Intermediates under contract
 services products are developed and produced on an exclusive basis
 under contract manufacturing services
 
 II.  Services (DDDSS) - Which consists of Collaborative Research
 Projects (CRP), Clinical Trials and Testing and Analysis services
 
 B) Secondary Segment:
 
 Geographical Segment
 
 The Company has identified the following geographical reportable
 segments:
 
 a) India-The Company sells Bulk Drugs and Intermediates and Fine
 Chemicals.
 
 b) U.S.A -The Company sells Intermediates
 
 c) Europe--The Company sells Bulk Drugs and Intermediates
 
 d) Others-The Company sells Bulk Drugs and Intermediates
 
 * Capital expenditure related to Amalgamation of Suven Nishtaa Pharma
 Pvt. ltd
 
 A) Related Parties
 
 1.  Subsidiary : Suven Nishtaa Pharma Pvt. Ltd
 
 2.  Key Managerial Personnel : Mr. Venkateswarlu Jasti
 
 Mrs. Sudha Rani Jasti
 
 Note: Figures in bracket indicates previous year figures
 
 NOTE 3: AMALGAMATION OF M/S. SUVEN NISHTAA PHARMA PVT. LTD.
 
 In terms of the Scheme of Amalgamation & Arrangement (Scheme) approved
 by orders dated 10.07.2012 of Hon''ble High Court of Andhra Pradesh,
 M/s. Suven Nishtaa Pharma Private Limited (Nishtaa) a wholly owned
 subsidiary whose core business is to carry on the business of
 Pharmaceutical Formulations contract services has been amalgamated with
 the Company with effect from 1st January, 2012.
 
 The amalgamation has been accounted for under the Pooling of Interest
 Method as prescribed by Accounting Standard (AS-14) Accounting for
 Amalgamation issued by the Institute of Chartered Accountants of
 India.
 
 In accordance with the said scheme all the assets, debts, liabilities,
 duties and obligations of Nishtaa have been vested in the Company
 with effect from 1st January, 2012 and have been recorded at their
 respective book values under pooling of Interest method of accounting
 for amalgamation. There were no differences in the accounting policies
 of Nishtaa and the Company.
 
 NOTE 4:
 
 On account of the Amalgamation of M/s. Suven Nishtaa Pharma Private
 Limited with the company w.e.f 01.01.2012, previous year figures are
 not comparable with the current year figures.
 
 NOTE 5:
 
 Previous year figures have been regrouped and reclassified wherever
 considered necessary to conform to this year''s classification.